1. Updated antimicrobial dosing recommendations for obese patients.
- Author
-
Castro-Balado A, Varela-Rey I, Mejuto B, Mondelo-García C, Zarra-Ferro I, Rodríguez-Jato T, and Fernández-Ferreiro A
- Subjects
- Humans, Anti-Infective Agents pharmacokinetics, Anti-Infective Agents administration & dosage, Anti-Infective Agents therapeutic use, Antifungal Agents pharmacokinetics, Antifungal Agents administration & dosage, Antifungal Agents therapeutic use, Antitubercular Agents pharmacokinetics, Antitubercular Agents administration & dosage, Antitubercular Agents therapeutic use, Antiviral Agents pharmacokinetics, Antiviral Agents administration & dosage, Antiviral Agents therapeutic use, Critical Illness, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Obesity drug therapy
- Abstract
The prevalence of obesity has increased considerably in the last few decades. Pathophysiological changes in obese patients lead to pharmacokinetic (PK) and pharmacodynamic (PD) alterations that can condition the correct exposure to antimicrobials if standard dosages are used. Inadequate dosing in obese patients can lead to toxicity or therapeutic failure. In recent years, additional antimicrobial PK/PD data, extended infusion strategies, and studies in critically ill patients have made it possible to obtain data to provide a better dosage in obese patients. Despite this, it is usually difficult to find information on drug dosing in this population, which is sometimes contradictory. This is a comprehensive review of the dosing of different types of antimicrobials (antibiotics, antifungals, antivirals, and antituberculosis drugs) in obese patients, where the literature on PK and possible dosing strategies in obese adults was critically assessed., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF